US FDA Gives Drug Makers Chance To Photoshop Clinical Trial 'Snapshots'
This article was originally published in SRA
Executive Summary
As the US Food and Drug Administration continues to refine its Drug Trials Snapshots transparency program, it is inviting sponsors to propose their own edits to the publicly available summaries of demographic subgroup clinical trial data for recently approved products.